Skip to main content
OpenTrials
Completed

NCT Number: NCT01129583

Botulinum Toxin as a Novel Treatment for Prevention of Post-Traumatic Elbow Stiffness

This is a randomized double blind placebo controlled study to investigate the hypothesis that injection of botulinum toxin A into the muscles surrounding the elbow following the surgical treatment of an elbow fracture will reduce postoperative stiffness and improve function.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Columbia University Medical Center

New York, 10032, United States

About this study

This is a randomized double blind placebo controlled prospective study in which botulinum toxin A (Botox®) or normal saline will be intraoperatively injected into the muscles surrounding the elbow following the surgical treatment of an elbow fracture or elbow fracture dislocation.

Eligible patients will be identified by the Principal Investigator in his practice or by fellows and residents from the clinic population and emergency department admissions. After providing informed consent, all subjects will undergo a baseline examination that will include a medical and orthopaedic history, physical examination, and radiographs. The surgical procedure itself will not differ from the standard care for elbow fractures. The only difference is injection of Botox® or normal saline into the muscles of the injured arm. Subjects will undergo post-operative evaluation at various intervals for up to two years. The study and control group will be compared to each other and to contralateral arms in regards to elbow range of motion, patient questionnaire scores (DASH) and an observer-based elbow scoring system (Broberg and Morrey).

Traumatic injury to the elbow resulting in a fracture or fracture/dislocation of the elbow often leads to a stiff elbow with limited function. Posttraumatic elbow stiffness is a common problem that is difficult to manage. The best way to decrease the morbidity is through prevention. An intraoperative injection of Botox® has been effective in treating upper limb spasticity disorders and may prevent the development of elbow stiffness, and decrease the need for future surgery to regain motion.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Capable of providing informed consent
  • 18 years old and older
  • Elbow fractures that require operative intervention including:
  • Supracondylar distal humerus fractures
  • Intra-articular distal humerus fractures
  • Proximal ulna and radius fractures

Exclusion criteria

  • Patients less than 18 years old
  • Injuries that do not normally require surgical repair
  • Patients with underlying spasticity
  • Patients with burns about the elbow
  • Patients with extensive soft tissue injuries of the elbow
  • Patients with head or spinal cord injuries
  • Myasthenia gravis, Eaton-Lambert, amyotrophic lateral sclerosis or any other disease that interferes with neuromuscular function
  • Use of aminoglycoside antibiotics or other drug therapies that interfere with neuromuscular function

Treatment and study plan

Botulinum Toxin Type A

Drug

Injection into the biceps brachii and brachialis immediately following the initial fracture surgery

Other names: Botox®

Saline

Drug

Injection into the biceps brachii and brachialis immediately following the initial fracture surgery

Primary outcomes

  1. Disabilities of the Arm, Shoulder, and Hand (DASH) Questionnaire

    Time frame: 1 year post-op

    The Disabilities of the Arm, Shoulder and Hand (DASH) Outcome Measure is a questionnaire designed to measure physical function and symptoms in patients with musculoskeletal disorders of the upper limb.

    The DASH is scored in two components: the disability/symptom questions (30 items, scored 1-5) and the optional high performance sport/music or work section (4 items, scored 1-5). The DASH disability/symptom score (0-100) is calculated by averaging all the scores, subtracting one and multiplying by 25. A score of 0 represents "no disability", while 100 represents "maximum possible disability".

Secondary outcomes

  1. Elbow Range of Motion

    Time frame: 3 months post-op

    Elbow flexion/extension active range of motion was assessed with the use of a standard goniometer with the center placed over the lateral epicondyle and the arms aligned with the long axis of the humerus and ulna, respectively. Full extension (arm completely straight) is defined as 0 degrees, and peak flexion is measured as the angle formed by the arm and forearm compared to a full straight arm.

  2. Broberg Morrey Composite Elbow Function Score

    Time frame: 6 months post-op

    Composite elbow function store that takes into account range of motion, stability, strength, and pain. Score ranges from 0 (worse possible function) to 100 (best possible function).

Sponsors and collaborators

Lead sponsor

Columbia University

Other

Collaborators

  • Allergan

Registry information

Official study title

Intraoperative Injection of Botulinum Toxin A (Botox) for the Prevention of Post-Traumatic Elbow Stiffness: A Randomized Double Blind Placebo Controlled Study

Important dates

Study start
2003
Primary completion
2009
Study completion
2010
First posted
May 24, 2010
Registry last updated
Mar 27, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.